These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15466491)

  • 1. Management of hepatitis C.
    Teo M; Hayes P
    Br Med Bull; 2004; 70():51-69. PubMed ID: 15466491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    Intervirology; 2013; 56(1):37-45. PubMed ID: 23037768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of hepatitis C virus infection in Korea.
    Suh DJ; Jeong SH
    Intervirology; 2006; 49(1-2):70-5. PubMed ID: 16166792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?
    Franchini M
    Hematology; 2006 Jun; 11(3):209-13. PubMed ID: 17325964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.
    Main J
    J Hepatol; 1995; 23 Suppl 2():32-5; discussion 35-6. PubMed ID: 8720292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of hepatitis C and the impact of anti-viral therapy.
    Boyer N; Marcellin P
    Forum (Genova); 2000; 10(1):4-18. PubMed ID: 10717254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribavirin in the treatment of hepatitis C.
    Abonyi ME; Lakatos PL
    Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of hepatitis C: patients with cirrhosis.
    Schalm SW; Fattovich G; Brouwer JT
    Hepatology; 1997 Sep; 26(3 Suppl 1):128S-132S. PubMed ID: 9305677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
    Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of interferon therapy in treatments for hepatitis C virus-related hepatocellular carcinoma].
    Kubo S; Nishiguchi S; Hirohashi K; Tanaka H; Shuto T; Takemura S; Shiomi S; Kinoshita H
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):1975-9. PubMed ID: 11791377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antiviral treatment of hepatitis C virus infection].
    Silvain C
    Rev Med Interne; 1999 Aug; 20 Suppl 3():331s-340s. PubMed ID: 10480183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of hepatitis C.
    Westbrook RH; Dusheiko G
    J Hepatol; 2014 Nov; 61(1 Suppl):S58-68. PubMed ID: 25443346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of curing hepatitis C infection.
    Marinho RT; Vitor S; Velosa J
    J Gastrointestin Liver Dis; 2014 Mar; 23(1):85-90. PubMed ID: 24689102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations.
    Khalid O; Bacon BR
    Clin Liver Dis; 2011 Aug; 15(3):573-83. PubMed ID: 21867937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection.
    Baffis V; Shrier I; Sherker AH; Szilagyi A
    Ann Intern Med; 1999 Nov; 131(9):696-701. PubMed ID: 10577333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on: "Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis".
    Ji F; Cai Z; Deng H
    Braz J Infect Dis; 2011; 15(4):410. PubMed ID: 21861021
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.